The B7-CD28 superfamily - PubMed (original) (raw)
Review
doi: 10.1038/nri727.
Affiliations
- PMID: 11910893
- DOI: 10.1038/nri727
Review
The B7-CD28 superfamily
Arlene H Sharpe et al. Nat Rev Immunol. 2002 Feb.
Abstract
The B7-1/B7-2-CD28/CTLA-4 pathway is crucial in regulating T-cell activation and tolerance. New B7 and CD28 molecules have recently been discovered and new pathways have been delineated that seem to be important for regulating the responses of previously activated T cells. Several B7 homologues are expressed on cells other than professional antigen-presenting cells, indicating new mechanisms for regulating T-cell responses in peripheral tissues. Some B7 homologues have unknown receptors, indicating that other immunoregulatory pathways remain to be described. Here, we summarize our current understanding of the new members of the B7 and CD28 families, and discuss their therapeutic potential.
Similar articles
- The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.
Carreno BM, Collins M. Carreno BM, et al. Annu Rev Immunol. 2002;20:29-53. doi: 10.1146/annurev.immunol.20.091101.091806. Epub 2001 Oct 4. Annu Rev Immunol. 2002. PMID: 11861596 Review. - The B7 family revisited.
Greenwald RJ, Freeman GJ, Sharpe AH. Greenwald RJ, et al. Annu Rev Immunol. 2005;23:515-48. doi: 10.1146/annurev.immunol.23.021704.115611. Annu Rev Immunol. 2005. PMID: 15771580 Review. - Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses.
Wang S, Chen L. Wang S, et al. Microbes Infect. 2004 Jul;6(8):759-66. doi: 10.1016/j.micinf.2004.03.007. Microbes Infect. 2004. PMID: 15207823 Review. - CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling.
Linsley PS, Bradshaw J, Urnes M, Grosmaire L, Ledbetter JA. Linsley PS, et al. J Immunol. 1993 Apr 15;150(8 Pt 1):3161-9. J Immunol. 1993. PMID: 7682233 - Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD, Starling GC, Williams LA, Hock BD, Hart DN. McLellan AD, et al. Eur J Immunol. 1995 Jul;25(7):2064-8. doi: 10.1002/eji.1830250739. Eur J Immunol. 1995. PMID: 7542604
Cited by
- COL1A1 is a prognostic biomarker and correlated with immune infiltrates in lung cancer.
Geng Q, Shen Z, Li L, Zhao J. Geng Q, et al. PeerJ. 2021 Mar 30;9:e11145. doi: 10.7717/peerj.11145. eCollection 2021. PeerJ. 2021. PMID: 33850663 Free PMC article. - T-cell tolerance in cancer.
Nurieva R, Wang J, Sahoo A. Nurieva R, et al. Immunotherapy. 2013 May;5(5):513-531. doi: 10.2217/imt.13.33. Immunotherapy. 2013. PMID: 23638746 Free PMC article. Review. - Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis.
Zhang XF, Pan K, Weng DS, Chen CL, Wang QJ, Zhao JJ, Pan QZ, Liu Q, Jiang SS, Li YQ, Zhang HX, Xia JC. Zhang XF, et al. Oncotarget. 2016 May 3;7(18):26670-9. doi: 10.18632/oncotarget.8476. Oncotarget. 2016. PMID: 27050369 Free PMC article. - PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.
Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, Ramanathan A, Chandrasekhar T, Dhudashiya AA, Talapati SR, Gowda N, Palakolanu S, Mani J, Srinivasrao B, Joseph D, Kumar N, Nair R, Atreya HS, Gowda N, Ramachandra M. Sasikumar PG, et al. Commun Biol. 2021 Jun 8;4(1):699. doi: 10.1038/s42003-021-02191-1. Commun Biol. 2021. PMID: 34103659 Free PMC article. - How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.
Gacerez AT, Arellano B, Sentman CL. Gacerez AT, et al. J Cell Physiol. 2016 Dec;231(12):2590-8. doi: 10.1002/jcp.25419. Epub 2016 Jun 2. J Cell Physiol. 2016. PMID: 27163336 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources